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Abstract
Hypoglycemia or glucoprivation triggers protective hormonal counterregulatory and feeding responses to aid the
restoration of normoglycemia. Increasing evidence suggests pertinent roles for the brain in sensing glucoprivation and
mediating counterregulation, however, the precise nature of the metabolic signals and molecular mediators linking central
glucose sensing to effector functions are not fully understood. Here, we demonstrate that protective hormonal and feeding
responses to hypoglycemia are regulated by BAD, a BCL-2 family protein with dual functions in apoptosis and metabolism.
BAD-deficient mice display impaired glycemic and hormonal counterregulatory responses to systemic glucoprivation
induced by 2-deoxy-D-glucose. BAD is also required for proper counterregulatory responses to insulin-induced
hypoglycemia as evident from significantly higher glucose infusion rates and lower plasma epinephrine levels during
hyperinsulinemic hypoglycemic clamps. Importantly, RNA interference-mediated acute knockdown of Bad in the brain
provided independent genetic evidence for its relevance in central glucose sensing and proper neurohumoral responses to
glucoprivation. Moreover, BAD deficiency is associated with impaired glucoprivic feeding, suggesting that its role in
adaptive responses to hypoglycemia extends beyond hormonal responses to regulation of feeding behavior. Together,
these data indicate a previously unappreciated role for BAD in the control of central glucose sensing.
Citation: Osundiji MA, Godes ML, Evans ML, Danial NN (2011) BAD Modulates Counterregulatory Responses to Hypoglycemia and Protective Glucoprivic
Feeding. PLoS ONE 6(12): e28016. doi:10.1371/journal.pone.0028016
Editor: Orian S. Shirihai, Boston University, United States of America
Received June 21, 2011; Accepted October 30, 2011; Published December 5, 2011
Copyright:  2011 Osundiji et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: MAO was supported by a post-doctoral fellowship from the Juvenile Diabetes Research Foundation (3-2010-472). NND is a recipient of the Burroughs
Wellcome Fund Career Award in Biomedical Sciences. This work was supported by United States National Institutes of Health grants K01CA10659 and
R01DK078081 (NND). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: nika_danial@dfci.harvard.edu
Introduction
Intensified lowering of blood glucose reduces the risk of chronic
complications of type 1 diabetes; however, clinical attempts to
achieve these benefits are limited by an increased risk of
hypoglycemia induced by aggressive insulin therapy, also known
as iatrogenic hypoglycemia [1,2]. Blood glucose levels are
normally maintained within narrow boundaries. Falling blood
glucose levels are rapidly sensed and a myriad of counter-
regulatory responses are triggered to help limit hypoglycemia and
aid restoration of normoglycemia. These protective responses
include physiological neurohumoral changes such as increased
release of glucagon, epinephrine and corticosterone, which act to
increase endogenous glucose production, limit tissue glucose
utilization, and trigger symptomatic responses, particularly hunger
[1,3]. Counterregulatory responses become impaired in some
diabetic patients leading to further susceptibility to hypoglycemic
episodes [3,4].
Increasing evidence suggests that the brain plays a predominant
role in sensing hypoglycemia or glucoprivation and initiating a
series of adaptive responses leading to the release of counter-
regulatory hormones and protective glucoprivic feeding
[5,6,7,8,9,10,11,12]. The precise mechanisms utilized by the brain
to detect glucose deficit and initiate counterregulatory responses
are under active investigation. Several putative frameworks for the
metabolic basis of central gluco-detection and the relevant
metabolic signals/messengers have been put forward [13].
Multiple neuroanatomical areas, including paraventricular and
ventromedial hypothalamus, nucleus of the solitary tract, dorsal
motor nucleus of the vagus and basolateral medulla and several
neural cell types play a pivotal role in this process
[5,6,7,8,9,10,11,12]. Genetic and pharmacologic approaches have
identified several molecular mediators of central glucose sensing
and counterregulation, including glucose transporter 2 (GLUT2)
[14,15], ATP-dependent K+ (KATP) channels [16,17,18], glucoki-
nase (GK) [19,20,21,22,23] and AMP-activated protein kinase
(AMPK) [24,25]. In addition, neurotransmitters such as c-amino
butyric acid (GABA) [26,27,28,29], glutamate [30], N-methyl D-
aspartate (NMDA) [31], as well as corticotrophin-releasing factor
receptors [32] have been implicated in hypoglycemia counter-
regulation. However, the precise neurochemical nature of these
responses and the coordinated function of the central glucose
sensing pathways are not completely defined.
The BCL-2 family of cell death regulators constitutes a critical
control point in the regulation of apoptosis [33,34]. Although
BCL-2 proteins are best known for their control of apoptosis, select
proteins in this family carry physiologic roles or ‘‘day jobs’’
separate from apoptosis, including nutrient metabolism [35,36,37].
We have previously reported a novel role for the pro-apoptotic
BCL-2 protein BAD (Bcl-2-associated death promoter) in islet b-
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cell glucose sensing through its association and activation of GK
[37]. In the brain, BAD is present in several anatomical locations,
including areas that are pivotal for brain nutrient sensing and
control of glucose counterregulation [38]. Using a combination of
genetic tools, including BAD-deficient mice and RNA interference
approaches, we investigated the role of BAD in the control of
counterregulatory hormonal and feeding responses to glucopriva-
tion. Our results suggest that BAD’s function in the brain is
required for proper hypoglycemia detection and initiation of
hormonal and feeding responses to glucoprivation.
Materials and Methods
Ethics Statement
All animal procedures were reviewed and approved by the
Institutional Animal Care and Use Committees of Dana-Farber
Cancer Institute and Vanderbilt University School of Medicine.
Animal protocols 05–052 and 09–072 were used for these studies.
Animals
The Bad 2/2 mice [39] were bred into the C57BL/6J genetic
background for at least 14 generations and were validated by
genome scanning to be 99.9% congenic with C57BL/6J. Wild
type C56BL/6J mice used for brain knockdown experiments were
purchased from the Jackson Laboratory (Bar Harbor, ME). Mice
were housed in pathogen-free facility and maintained on a 12 h
light/dark cycle.
Glycemic Response to Glucoprivation
We studied 10 week old male Bad 2/2 and Bad +/+ mice (weight:
25.760.6 vs 25.160.5 g, respectively). Non-fasted Bad 2/2 and
Bad +/+ mice had food taken away 30 min prior to i.p. injection of
150 mg/kg 2DG. Blood glucose levels were then monitored at
15 min intervals over the ensuing 60 minutes from tail vein blood
using an automated glucose monitor (OneTouch Ultra, LifeScan).
Hormonal Response to Glucoprivation
Non-fasted Bad 2/2 and Bad +/+ mice had food taken away
immediately prior to i.p. injection of 150 mg/kg 2DG or saline.
Blood collection and hormone monitoring were carried out as
described below.
L-Arginine Stimulation Studies
Overnight fasted Bad 2/2 and Bad +/+ mice received i.p. injection
of 3 g/kg L-arginine. Mice were anesthetized after 10 min by a brief
exposure to isoflurane as described below and blood samples were
collected via retro-orbital sinus puncture for glucagon measurements.
Blood Collection for Glucose and Hormonal Assays in
Glucoprivation and L-Arginine Stimulation Studies
Blood samples were collected using tail bleeds when blood
glucose was continuously measured and small blood volume was
required (as in Fig. 1A). Retro-orbital collection was used when
relatively larger blood volume was needed for measurement of
multiple serum hormones and blood glucose levels at one time
point only. Briefly, following anesthetic induction with isoflurane
(up to 5% in oxygen), blood samples were rapidly collected in the
presence of 1 mg/ml aprotinin and 1 mM EDTA using retro-
orbital puncture. Anesthesia was only maintained at the beginning
of blood collection and retro-orbital puncture and blood sampling
lasted ,120 seconds. Serum samples were prepared and glucagon
levels determined by RIA (Linco), epinephrine and corticosterone
levels were determined by ELISA.
Glucagon Secretion Studies in Primary Islet Cultures
Bad 2/2 and Bad +/+ primary islets were isolated by the
collagenase method as previously described [37]. Glucagon was
measured using a slight modification of a previously described
method [18]. Briefly, freshly isolated islets were preincubated at
37uC for 60 min in Krebs–Ringer bicarbonate buffer, pH 7.4,
supplemented with 20 mM HEPES, 0.05% bovine serum albumin
and 7 mM glucose. The islets were then transferred to 500 ml of
the Krebs–Ringer bicarbonate buffer containing 7 mM glucose
and 50 mM carbachol, 16.7 mM glucose or 1 mM glucose in the
presence of 500 KIU/ml of aprotinin and incubated for 60 min.
Aliquots of the medium were then removed for glucagon
measurements. For each condition, 15 tubes containing 10
islets/tube were assessed. Data shown are cumulative of 3
independent islet isolations.
Hyperinsulinemic Hypoglycemic Clamp Studies
Hypoglycemic clamps were performed as previously described
[40] using 12 week old male Bad 2/2 and Bad +/+ mice (weight:
25.761.1 vs 24.261 g, respectively, p= non-significant). Briefly,
five days prior to the clamp study, catheters were inserted into the
carotid artery and jugular vein. Chronically catheterized conscious
mice were subjected to clamps under conscious and unstressed
conditions after 6 hr fasting. A 1 mCi bolus of [3-3H] glucose was
given at t=2120 min before insulin infusion, followed by a
0.05 mCi/min infusion for the duration of the study. After
obtaining a baseline plasma glucose concentration (t =20 min),
a continuous infusion of insulin was initiated (10 mU
~
kg~min) into
the jugular vein. Plasma glucose levels were monitored every
10 min, and glucose was infused into the jugular vein at a variable
rate to reach the target plasma glucose concentration (50 mg/dl).
Mice received a continuous infusion of heparinized saline-washed
erythrocytes into the jugular vein from donor animals to prevent a
fall of hematocrit. Blood samples were also collected from the
carotid artery for measurement of [3-3H] glucose, insulin (RIA;
Millipore, Billerica, MA) and counterregulatory hormones includ-
ing glucagon (RIA; Millipore, Billerica, MA), epinephrine,
norepinephrine (HPLC; [41]), and corticosterone (RIA; MP
Biomedicals, Orangeburg NY). Briefly, after deproteinization of
plasma with barium hydroxide [Ba(OH)2, 0.3 N] and zinc sulfate
[ZnSO4, 0.3 N], plasma [3-
3H] glucose extracts were dried and
radioactivity was determined by liquid scintillation counting
(Packard TRI-CARB 2900TR) with Ultima Gold (Packard) as
scintillant. Glucose appearance (Ra) and disappearance (Rd) were
determined using Steele nonsteady-state equations. Endogenous
glucose production (endoRa) was determined by subtracting the
glucose infusion rate (GIR) from total Ra [42].
Adenovirus Production
Adenoviruses carrying Bad shRNA or scrambled control were
constructed using the Adeno-X Expression Systems 2 with Creator
Technology (Clonetech). Briefly, 19 bp sequences based on the Bad
coding sequence were designed using Block-it RNAi designer
software (Invitrogen). Oligonucleotides were then designed according
to the knockout clone and confirm PCR kit (Clontech) and cloned
into RNAi-Ready pSIERN-DNR-Ds Red-Express Donor vector.
Virus amplification, purification, titration and verification were
carried out using the services of ViraQuest Inc. (North Liberty, IA).
RNA-Interference Mediated Knockdown of Bad in the
Brain
9 week old male C57BL/6J mice underwent stereotactic surgery
for implantation of an indwelling bilateral guide cannula into the
Brain BAD Mediates Glucose Counterregulation
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brain according to the following stereotactic coordinates: 1.3 mm
posterior to bregma, 60.5 mm from midline. The goal was to
create whole brain knockdown of Bad. The infusion coordinates
where targeting medial hypothalamus, immediately neighboring
the third ventricle, which will facilitate whole brain re-distribution.
After recovery, mice received brain infusion of adenoviruses
containing Bad shRNA or scrambled control at a dose of 26107
plaque forming units/mouse. We selected an infusion volume
(1 ml/mouse) to allow whole brain distribution of infusate. We
validated the efficiency of brain knockdown by monitoring Bad
mRNA levels in the brainstem and frontal cortex as representative
hindbrain and forebrain areas, respectively. Seven days after virus
delivery, mice were subjected to glucoprivation as described
above.
RNA Analysis
RNA was prepared from brain samples and quantitative PCR
for Bad expression was performed as previously described [37].
Primers for cyclophilin served as internal controls for the quality of
RNA. Primer sequences are available upon request.
Glucoprivic Feeding Studies
We studied 11 week old male Bad 2/2 and Bad +/+ mice (weight:
26.460.4 vs 25.560.4 g, respectively, p = non-significant). Gluco-
privic feeding experiments were conducted between 10 AM and 5
PM. Ad libitum-fed Bad 2/2 and Bad +/+ mice received i.p. injection
of 150 mg/kg 2DG or saline. Food intake over the ensuring
4 hours was monitored by weighing the food remaining in the
cages [19]. Paper towel bedding was used during glucoprivic
feeding tests to aid the determination of in-cage food waste.
Statistics
Data are presented as means 6 s.e.m. Glucose excursion curve
during glucoprivation studies in Bad 2/2 and Bad +/+mice (Fig. 1A)
were analyzed by repeated measures ANOVA. Statistical analysis
for all other experiments was performed using two tailed Student’s
t-test.
Results
Impaired Glycemic and Hormonal Responses to
Glucoprivation in BAD-Deficient Mice
The effect of BAD on glucose sensing in b-cells [37] prompted
investigation of its role in neuroendocrine glucose sensing and
adaptive responses to hypoglycemia. Initial analysis of tail blood
glucose concentration in response to a glucoprivic signal induced
by intraperitoneal (i.p.) administration of 150 mg/kg 2-deoxy
glucose (2DG) indicated small but significant differences with
lower values in Bad 2/2 mice compared with Bad +/+ counterparts
(Fig. 1A). The rise in blood glucose in response to glucoprivation
Figure 1. Impaired glycemic and hormonal counterregulatory responses to glucoprivation in BAD-deficient mice. (A) Glycemic
response to systemic glucoprivation in Bad 2/2 and Bad +/+ mice. Tail blood glucose was monitored over a 60 min period following intraperitoneal
(i.p.) administration of 2DG (150 mg/kg) to Bad 2/2 (n = 12) and Bad +/+ (n = 14) mice. p,0.01; Bad 2/2 vs Bad +/+, two-way repeated measures
ANOVA. (B–D) Hormonal responses to systemic glucoprivation. Serum glucagon (B), epinephrine (C), and corticosterone (D) levels were measured in
retro-orbital blood samples collected 30 min after i.p. administration of 2DG (150 mg/kg) or saline to Bad 2/2 and Bad +/+ mice (n = 7–17 per group).
*p,0.05; **p,0.01; ***p,0.001, unpaired two tailed t-test.
doi:10.1371/journal.pone.0028016.g001
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stems from a counterregulatory neurohumoral response, which
acts to increase endogenous glucose production and reduce
peripheral glucose uptake [9]. Our study design in these
experiments did not allow us to examine the contribution of
glucose clearance by peripheral tissue and glucose production to
the in vivo response to glucoprivation, however, we measured
counterregulatory hormones to determine whether altered glyce-
mic response in Bad 2/2 mice might be related to differences in
neurohumoral responses. Serum concentrations of counterregula-
tory hormones glucagon, epinephrine and corticosterone were
measured at 30 minutes following 2DG administration in light of
published reports that this time point elicits the strongest glucagon
response [14]. Importantly, to discriminate between impaired
glucoprivic responses and generalized stress responses, mice were
anesthetized 30 minutes following saline or 2DG administration
and blood samples collected. This experimental setup enabled us
to distinguish between hormonal responses that result from general
stress associated with animal handling, i.p. injections, and
anesthesia that will be apparent in saline-treated animals, and
the hormonal changes that are specific to glucoprivation appearing
only with 2DG administration. In wild type mice, 2DG triggered a
significant rise in plasma glucagon and epinephrine levels while in
Bad 2/2 mice, these hormonal responses to glucoprivation were
significantly blunted (Fig. 1B, C). Notably, serum epinephrine
levels were comparable in saline-treated Bad +/+ and Bad 2/2 mice
that were similarly anesthetized prior to blood collection (saline
arm, Fig. 1C). These results suggest that alterations in 2DG-
induced hormonal responses in BAD-deficient mice stem from
changes in counterregulatory responses and cannot be explained
by global alterations in catecholamine levels, which would be
predicted in response to generalized stress such as anesthesia.
Glucagon and epinephrine responses are the foremost line of
defense against glucoprivation. If glucose deficit persists, cortico-
sterone release is triggered to compliment glucagon and
epinephrine. 150 mg/kg 2DG induces a modest glucoprivic threat
[14] that is not sufficient to induce corticosterone response in
control mice (Fig. 1D). However, in Bad 2/2 mice, this level of
glucoprivation mounted a significant corticosterone response
(Fig. 1D). This is consistent with impaired glucagon and
epinephrine responses in these mice, transforming the signal from
150 mg/kg 2DG to a greater glucoprivic threat. These data are
also corroborated by lower glucose levels under these conditions
(Fig. 1A). Thus, alterations in counterregulatory hormones in
BAD-deficient mice parallel changes in glycemic profiles in
glucoprivation studies. These observations suggest a role for
BAD in proper detection of hypoglycemia and underscore its
relevance for mediating hormonal responses to systemic glucopri-
vation.
Comparable Glucagon Secretion in Primary Bad +/+ and
Bad 2/2 Islet Cultures
Hypoglycemia-induced glucagon secretion is regulated by both
autonomic input from the brain as well as direct glucose sensing by
pancreatic islets [14,16,43,44,45]. As Bad 2/2 mice are a genetic
model of total body BAD deficiency, the impaired glucagon
response to glucoprivation could stem from defects in pancreatic
or extrapancreatic glucose sensors. To determine the potential
contribution of altered a-cell function to impaired glucagon
response, the glucagon secretory capacity of primary Bad +/+ and
Bad 2/2 islets in response to lowering glucose concentrations from
high (16.7 mM) to low (1 mM) levels was assessed [18]. BAD-
deficient islets displayed comparable glucagon secretory response
to that observed in control islets (Fig. 2A). These observations
suggest that the impaired glucagon response to glucoprivation in
Bad 2/2 mice is less likely due to a cell-intrinsic defect in a-cells.
Furthermore, glucagon response to the synthetic choline ester
carbachol was comparable in Bad 2/2 and Bad +/+ islets (Fig. 2A).
Thus, both the a-cell glucose sensing properties and its response to
autonomic input are unaltered in Bad 2/2 mice.
In addition to hypoglycemia, certain amino acids, in particular
L-arginine stimulate glucagon secretion [46]. Glucagon secretion
in response to intraperitoneal administration of L-arginine was
subsequently examined to determine whether impaired glucagon
release in Bad 2/2 mice is specific for glucose-related signals or
more general to nutrient-derived stimuli. Serum glucagon levels
were measured at 10 minutes following arginine stimulation as this
time point has been previously shown to display the strongest
glucagon response [47]. L-Arginine-induced glucagon secretion
was similar in Bad +/+ and Bad 2/2 mice (Fig. 2B), indicating that
the nutrient sensing defect and the attendant impairment of
glucagon response in the absence of BAD are glucose-selective.
BAD-Dependent Counterregulatory Responses to Insulin-
Induced Hypoglycemia
While 2DG-induced glucoprivation is a useful experimental
model of hypoglycemia, it does not precisely mimic the clinically
relevant stimulus experienced by diabetic patients; namely insulin-
induced hypoglycemia. To assess the role of BAD in the control of
counterregulatory responses to insulin-induced hypoglycemia, a
hyperinsulinemic hypoglycemic clamp approach was pursued.
Figure 2. Glucagon secretion in response to glucose and
arginine. (A) Glucagon secretion in primary Bad 2/2 and Bad +/+ islets.
Data are mean 6 s.e.m and represent cumulative values from 3
independent islet isolations. Glc, glucose. *p,0.05; **p,0.01, unpaired
two tailed t-test (B) Glucagon secretion during L-arginine stimulation of
Bad 2/2 and Bad +/+ mice (n = 4–7 per group). ***p,0.001, unpaired
two tailed t-test.
doi:10.1371/journal.pone.0028016.g002
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Plasma glucose levels indicated comparable hypoglycemia was
achieved and maintained in Bad 2/2 and Bad +/+ mice throughout
the analysis (Fig. 3A).
Within the last 30 minutes of the clamp period, glucose infusion
rate (GIR) required to maintain hypoglycemia was significantly
higher in Bad 2/2 mice (Fig. 3B). Differences in GIR may stem
from changes in endogenous glucose output and/or peripheral
glucose uptake. Examination of glucose tracers incorporated in the
clamp study indicated comparable glucose turnover rates in Bad 2/2
and Bad +/+ mice at both baseline (average turnover 210 to 0 min,
2563 vs 2464 mg/kg/min, respectively) and at the end of the
clamp period (average turnover 80–120 min, 2161 vs 2161 mg/
kg/min, respectively). As expected, endogenous glucose produc-
tion was suppressed by the high dose of insulin during these
studies, however, Bad 2/2 mice showed greater suppression (80–
120 min, 162 vs 561 mg/kg/min, p = 0.05, Bad 2/2 vs Bad +/+,
respectively). Thus, the higher GIR in Bad 2/2 mice during the
last 30 minutes of the clamp period may coincide with greater
suppression of endogenous glucose output. These results are
consistent with the idea that BAD deficiency is associated with
counterregulatory deficit.
At 30 minutes during hypoglycemic clamp, plasma glucagon
concentrations showed a lower trend Bad 2/2 mice (Fig. 3C). In
these studies, glucagon responses to hypoglycemia in both
genotypes were generally higher than typically reported in similar
studies in mice. However, marked differences both between and
within outbred mouse strains in responses to hypoglycemia have
been reported [48], indicating the importance of appropriate
littermate controls in these mouse clamp studies. Epinephrine
levels at 30 minutes during hypoglycemic clamp were also
measured and found to be significantly blunted in Bad 2/2 mice
(Fig 3D). Of note, basal levels of glucagon and epinephrine were
comparable in both genotypes with glucagon at 78612 and
130658 pg/ml and epinephrine at 41619 and 43621 pg/ml
(Bad 2/2 vs Bad +/+, mice, p.0.05).
Overall, these results indicate BAD deficiency is associated with
impaired counterregulatory responses to insulin-induced hypogly-
cemia, a clinically relevant glucoprivic threat. The counter-
regulatory deficit in Bad 2/2 mice might be associated with
greater suppression of endogenous glucose production in response
to high dose of insulin in the experimental setting used for
hyperinsulinemic hypoglycemic clamp studies. In addition, the
possible contribution of reduced sympathetic tone as suggested by
lower epinephrine levels in Bad 2/2 mice and the associated
changes in peripheral insulin sensitivity to altered counter-
regulatory responses in these animals cannot be excluded.
Impaired Counterregulatory Responses to Glucoprivation
Following Acute Central Knockdown of Bad
To determine whether abnormalities in hypoglycemia counter-
regulation in Bad 2/2 mice are directly due to central BAD
deficiency per se or to potential secondary effects of total body BAD
deficiency, the functional outcome of acute central Bad ablation
was investigated (Fig. 4A). This genetic approach also helped
determine whether BAD-dependent modification of brain glucose
sensing as compared with pancreatic or extrapancreatic glucose
sensors such as the portal vein is sufficient to phenocopy the
defects in counterregulatory responses to glucoprivation observed
in BAD-deficient mice.
Stereotactic delivery of adenoviruses bearing shRNA against
Bad to C57/BL6J wild type mice effectively diminished its
Figure 3. Impaired counterregulatory responses to insulin-induced hypoglycemia in BAD-deficient mice. Plasma glucose levels (A) and
glucose infusion rate (GIR) (B) in Bad 2/2 and Bad +/+ mice subjected to hyperinsulinemic hypoglycemic clamp analysis. Plasma glucagon (C) and
epinephrine (D) levels at 30 min during the clamp period. *p,0.05; **p,0.01, Bad 2/2 vs Bad +/+ mice (n = 9 per group), unpaired two tailed t-test.
doi:10.1371/journal.pone.0028016.g003
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expression in the brain compared with a scrambled control
sequence (Fig. 4B). Subsequent analysis of glycemic and glucagon
responses to systemic glucoprivic challenge indicated that acute
diminution of Bad expression in the brain is sufficient to impair
hypoglycemia counterregulation. In response to intraperitoneal
administration of 150 mg/kg 2DG, mice with brain knockdown of
Bad failed to mount a glycemic response (Fig. 4C). Of note, the
range of glucose values obtained using retro-orbital blood samples
in these studies were significantly lower than tail blood glucose
levels (Fig. 4C vs 1A). This is consistent with previous reports
indicating that collection sites influence blood glucose concentra-
tion range [49]. Nonetheless, both BAD-deficient mice and
animals with brain Bad knockdown had impaired glycemic
response to glucoprivation compared with control cohorts
independent of blood collection methods. Diminished expression
of Bad in the brain was also linked to impaired glucoprivic
stimulation of glucagon release (Fig. 4D). Importantly, glucagon
levels were comparable in Bad shRNA and control cohorts
administered with saline and similarly handled and treated for
blood collection (saline arm, Fig. 4D), indicating that BAD-
dependent changes in glucagon are selective to glucoprivic
responses rather than an outcome of generalized stress responses.
Taken together, these findings indicate that brain-specific acute
knockdown of Bad is sufficient to impair detection of hypoglycemia
and initiation of hormonal counterregulatory responses and
highlight a role for central expression and function of BAD in
brain glucose sensing.
Regulation of Glucoprivic Feeding by BAD
In addition to hormone release, glucoprivation triggers
important symptomatic responses, including hunger, which is
arguably the most important individual symptom of hypoglycemia
Figure 4. Impaired counterregulatory responses to glucoprivation following acute central knockdown of Bad. (A) Schematic
representation of the experimental design. (B) Relative Bad mRNA levels in the frontal cortex and the brainstem (as representative fore- and hindbrain
areas, respectively) 7 days after brain infusion of adenoviruses bearing Bad shRNA or control scrambled (scr or scrmbl) sequence, n = 7–9 mice per
group. (C, D) Glycemic (C) and glucagon (D) responses to 2DG-induced glucoprivation in mice after stereotactic delivery of adenoviruses as in (A),
n = 5–6 (saline) and n=12–13 (2DG). Glucose and hormone values were assayed 30 min after 2DG (150 mg/kg) administration. *p,0.05; **p,0.01;
***p,0.001, unpaired two tailed t-test.
doi:10.1371/journal.pone.0028016.g004
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[1]. Several lines of evidence suggest that the control of food intake
is predominantly driven by the central nervous system [50,51].
The brain integrates a myriad of signals [52,53], including glucose
availability to regulate food intake [54]. To determine the extent
to which adaptive responses to hypoglycemia were altered by the
absence of BAD, protective feeding responses to glucoprivation
were also examined. Basal cumulative food intake over a 24 hour
period was comparable in Bad 2/2 and Bad +/+ mice (data not
shown), indicating that loss of BAD does not globally alter feeding
behavior. However, basal light cycle food intake during the 4 hour
period of 2DG-induced glucoprivation was significantly lower in
Bad 2/2 mice compared with wild type controls (Fig. 5). Thus,
changes in feeding behavior in face of BAD deficiency selectively
manifest within the context of glucoprivation. These data indicate
that the failure to mount proper responses to hypoglycemia in the
absence of BAD extends beyond neurohumoral responses to
effector functions such as glucoprivic feeding that are also
regulated by central glucose sensing.
Discussion
Here, we provide two independent lines of genetic evidence using
Bad-null mice and shRNA-mediated whole brain knockdown of Bad
in wild type mice that uncover a previously unappreciated role for
this molecule in the control of hypoglycemia counterregulation. The
relevance of BAD in this adaptive response is apparent in two
different models of systemic hypoglycemia; 2DG-induced glucopri-
vation and the more clinically relevant paradigm of insulin-induced
hypoglycemia. Our findings suggest that several functional effectors
of central glucose sensing are modified by BAD, including
neurohumoral responses culminating in secretion of glucagon and
epinephrine, as well as glucoprivic feeding. The finding that brain
knockdown of Bad impairs glycemic and glucagon responses to
glucoprivation is consistent with the idea that BAD expression and
function in the brain is required for proper hypoglycemia counter-
regulation and suggests the involvement of central gluco-detection.
However, the precise neuroanatomical region(s) mediating BAD’s
effect in central glucose sensing and the underlying neurocircuitry
remain to be determined. Importantly, our studies do not exclude
potential involvement of other glucose sensors outside the brain
such as those reported in the portal vein.
The initial detection of defective hypoglycemia counterregulation in
BAD-deficient mice raised important questions regarding the
contribution of non-glycemic and generalized stress responses versus
glucose-specific changes in neuroendocrine responses. Two indepen-
dent lines of observations suggest that the hormonal changes in these
mice are less likely caused by non-glycemic stress. First, the epinephrine
response to anesthetic stress is unaffected in Bad 2/2 mice (saline
administered Bad +/+ vs Bad 2/2mice, Fig. 1C). Second, the glucagon
secretory response to L-arginine stimulation is preserved in these
animals (Fig. 2B), congruent with the idea that BAD-dependent
changes in glucagon responses are specific for glucose-related stimuli.
In light of our previous findings that direct binding and activation
of GK by BAD regulates glucose sensing and insulin secretion in b-
cells [37], an initial prediction was that loss of BAD would
phenocopy the neuroendocrine alterations associated with phar-
macologic or genetic interference with GK [19,21,22]. Surprisingly,
the main functional effector of central glucose sensing that appears
to phenocopy loss-of-GK function in BAD-deficient mice is
impaired glucoprivic feeding [22]. As for neurohumoral responses
to insulin-induced hypoglycemia, diminution of GK [21] and loss of
BAD have divergent effects. This suggests that BAD’s role in the
control of hormonal responses to hypoglycemia may be indepen-
dent of GK. Several possibilities may explain the divergent effect of
BAD and GK in this setting. For example, BAD has a much wider
expression pattern in the brain compared with GK [38,55,56]. It is
also possible that the neural mechanisms and the predominant
neuroanatomical regions and glucose sensors in charge of
glucoprivic feeding behavior versus hormonal responses are not
exactly identical or redundant. This idea is consistent with other
lines of evidence that have suggested separate mechanisms may
control feeding versus hormonal responses [9]. Consequently, BAD-
regulation of glucoprivic feeding may involve its partnership with
GK, while its effects on hormonal responses may be mediated by
other mechanisms. Furthermore, recent findings suggest that BAD
may regulate certain aspects of neuronal functions particularly
NMDA receptor-dependent synaptic transmission [57]. This may
be relevant within the context of neurohumoral responses during
hypoglycemia as central glutaminergic signaling via NMDA
receptors controls neuroendocrine secretion [58], including coun-
terregulatory responses to hypoglycemia [30,31]. Lastly, BAD-
dependent modulation of calcium buffering [59] may further shape
the nature of calcium signals in these neurochemical responses.
Future studies and new genetic tools are required to test each of the
aforementioned possibilities and delineate the predominant mech-
anism(s) underpinning BAD’s role in hypoglycemia counterregula-
tion. Further dissection of BAD as a molecular modulator of brain
glucose sensing and its potential functional collaboration with other
known glucose sensors may uncover novel insights as well as new
therapeutic targets for the control of hypoglycemia caused by
aggressive insulin therapy.
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